Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer Academic Article uri icon

Overview

MeSH Major

  • Prostate-Specific Antigen
  • Prostatic Neoplasms

abstract

  • The results suggest that posttherapy PSA declines can be used as a surrogate end point to evaluate new agents in hormone-refractory prostate cancer. The criteria for response need prospective validation in phase III trials.

publication date

  • December 1993

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed ID

  • 7683043

Additional Document Info

start page

  • 607

end page

  • 15

volume

  • 11

number

  • 4